Literature DB >> 11918233

Evaluation of the prognostic factors after thymoma resection.

S Matsushima1, H Yamamoto, K Egami, S Suzuki, S Tanaka.   

Abstract

We discuss the prognostic factors of thymoma clinicopathologically. Regarding the survival rate by the clinical stage classification of Masaoka, significant correlation was made between stage I and stage III (P < 0.05) and stage I and stage IVa (P < 0.03). The tumor resectability was classified into complete and incomplete resection, and a significant difference was shown by the survival rate of the complete resection at P < 0.0001. Regarding the survival rate by the invasive organ of the tumor, significant correlation was made between no invasion and the great vessel invasion (P < 0.0004) and between invasion except for the great vessel and great vessel invasion (P < 0.004). As for the histological type, the tendency in which the epithelial cell type predominancy increased with the progress of the clinical stage was shown. A significant correlation was not shown in the evaluation by adjuvant therapy. However, recently we have done chemotherapy and/or radiotherapy periodically for invasive thymoma.

Entities:  

Mesh:

Year:  2001        PMID: 11918233

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  3 in total

Review 1.  Thymic neoplasms: a clinical update.

Authors:  Mark Mikhail; Yasmin Mekhail; Tarek Mekhail
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

Review 2.  Pediatric thymomas: report of two cases and comprehensive review of the literature.

Authors:  Annabelle L Fonseca; Doruk E Ozgediz; Emily R Christison-Lagay; Frank C Detterbeck; Michael G Caty
Journal:  Pediatr Surg Int       Date:  2013-12-10       Impact factor: 1.827

Review 3.  Myasthenia gravis associated with invasive malignant thymoma: two case reports and a review of the literature.

Authors:  Said R Beydoun; Hui Gong; Nazely Ashikian; Richard Alan Rison
Journal:  J Med Case Rep       Date:  2014-10-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.